Toxin tied to deadly staph pneumonia under the microscope
NCT ID NCT02798497
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at 234 patients with severe staph pneumonia to see if a toxin called PVL makes the disease worse. Researchers compared survival rates between patients infected with PVL-producing bacteria and those without. They also collected blood samples to explore whether genetics play a role in how sick people get.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict which patients with staph pneumonia are at highest risk and guide treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not change current medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
234 people
The number who actually took part.
- Started
-
May 2011
- Finished
-
Dec 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 months to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 2-month-old patient at minimum and weighing at least 5 kg * Informed consent * Subjects affiliated (or beneficiary) to a national medical insurance * Presence of clinical, biological and radiological signs of pneumopathy to S. aureus whose clinical state justifies a hospitalization in a ICU or in a reanimation * Presence of PVL- positive S.aureus producer (for immunogenetic study) Exclusion Criteria: * Patients infected by the HIV * Patients hospitalized for more than 48 hours at the time of the diagnosis of pneumonia, * Patients hospitalized during the previous three months excepted outpatients
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Staphylococcus aureus pneumonias are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre National de Références des Staphylocoques Centre de Biologie et Pathologie Est 59 bd Pinel
Bron, 69677, France